Form 4: Moderna Director Afeyan Executes Stock Option Exercise

Director Noubar Afeyan exercised 9,263 stock options and subsequently sold the shares via Flagship Pioneering.

Summary

• Director Noubar Afeyan, through Flagship Pioneering, LLC, exercised 9,263 stock options at a strike price of $19.15.
• The acquired shares were immediately sold at a market price of $46.84 per share.
• The transaction was executed on May 21, 2026, to address options expiring on August 10, 2026.
• Following the transaction, the reporting person maintains significant indirect holdings through various Flagship entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative transaction related to expiring equity compensation rather than a signal of fundamental change.

Positives

• The exercise of options demonstrates the utilization of vested equity compensation before expiration.
• The transaction was executed in a transparent manner consistent with regulatory requirements.

Negatives

• The immediate sale of the acquired shares indicates a lack of long-term retention of the newly exercised equity.

Risks

• Market volatility may impact the value of remaining holdings held by Flagship entities.
• Future expiration of other equity instruments could lead to further selling activity.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person disclaims beneficial ownership of the shares held by Flagship entities except to the extent of his pecuniary interest.

Industry Context

StockSavvy.ai notes that insider selling following option exercises is a common practice among biotech executives to manage tax liabilities and diversify portfolios, and does not necessarily reflect a change in sentiment regarding the company's long-term prospects.

Comparison to Industry Standards

• The transaction is consistent with standard executive compensation management practices in the biotechnology sector.
• The volume of shares sold is relatively small compared to the total holdings of the reporting person and associated entities.

Related Party Transactions

• The shares are held by Flagship Pioneering, LLC, which is controlled by the reporting person.

Stakeholder Impact

• Minimal impact on shareholders as the transaction represents a small portion of the director's total indirect holdings.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

Moderna, MRNA, Insider Trading, Form 4, Noubar Afeyan, Flagship Pioneering, Equity Exercise